$11.1 M

HEB Mkt cap, 20-Sep-2018

$89 K

Hemispherx BioPharma Revenue Q2, 2018
Hemispherx BioPharma Net income (Q2, 2018)-5.1 M
Hemispherx BioPharma EBIT (Q2, 2018)-5.8 M
Hemispherx BioPharma Cash, 30-Jun-20183.6 M

Hemispherx BioPharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150 k197 k133 k92 k

Revenue growth, %

31%(32%)(31%)

R&D expense

8.4 m9 m8 m5.1 m

General and administrative expense

7.7 m9.1 m7.1 m7.7 m

Operating expense total

16.1 m18 m15.2 m12.8 m

EBIT

(17.2 m)(19.1 m)(16.7 m)(13.8 m)

EBIT margin, %

(11445%)(9695%)(12519%)(15004%)

Interest expense

16 k11 k3 k

Net Income

(16.2 m)(17.5 m)(15.2 m)(7.5 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

36 k45 k36 k47 k23 k39 k15 k22 k84 k90 k56 k89 k

R&D expense

2.3 m1.9 m2.7 m2.4 m2 m1 m900 k1.3 m1.4 m787 k855 k2.2 m

General and administrative expense

2.5 m2.2 m1.9 m2 m1.7 m2.4 m1.6 m1.6 m1.7 m1.6 m1.6 m3.3 m

Operating expense total

4.8 m4.1 m4.6 m4.4 m3.7 m3.5 m2.5 m3 m3.1 m2.7 m2.6 m5.9 m

Depreciation and amortization

739 k

EBIT

(5.1 m)(4.3 m)(4.9 m)(4.9 m)(4 m)(3.7 m)(2.8 m)(3.2 m)(3.2 m)(2.7 m)(2.6 m)(5.8 m)

EBIT margin, %

(14125%)(9620%)(13675%)(10428%)(17317%)(9433%)(18760%)(14664%)(3858%)(2947%)(4589%)(6513%)

Interest expense

3 k3 k2 k1 k

Interest income

4 k55 k

Net Income

(8.8 m)(13 m)(3.4 m)(8.3 m)(12.1 m)(2.2 m)(3.5 m)(6.3 m)(2.8 m)(1.3 m)(2.7 m)(5.1 m)

Hemispherx BioPharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

803 k2.2 m2.1 m2.4 m

Accounts Receivable

Inventories

399 k335 k

Current Assets

18.6 m16.5 m10.6 m6.9 m

PP&E

5.1 m4.6 m11.2 m9.5 m

Total Assets

31.9 m29.4 m22.8 m18.9 m

Accounts Payable

1.3 m2.1 m1.2 m887 k

Short-term debt

Current Liabilities

2.5 m4.4 m2.4 m2.4 m

Long-term debt

Additional Paid-in Capital

289.6 m302.7 m313.2 m316 m

Retained Earnings

(260.3 m)(277.8 m)(293 m)(300.5 m)

Total Equity

20.4 m15.5 m

Financial Leverage

1.1 x1.2 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

2.6 m1.3 m2.9 m1.8 m1.2 m1 m1.5 m4.5 m776 k503 k4 m3.6 m

Accounts Receivable

41 k42 k29 k35 k

Inventories

626 k

Current Assets

20.5 m17.7 m17.9 m17.1 m14 m9.5 m10.7 m9.3 m5.2 m3.7 m5.7 m5.3 m

PP&E

4.8 m4.7 m11.8 m11.7 m11.5 m10.9 m10.1 m9.8 m9.3 m8.8 m8.4 m8.1 m

Total Assets

33.5 m30.6 m30.8 m29.9 m26.5 m21.5 m21.9 m21.6 m16.9 m14.7 m16.3 m15.7 m

Accounts Payable

1.5 m2.4 m2.3 m1.6 m1.5 m1.4 m1.4 m1 m927 k460 k850 k689 k

Short-term debt

1.5 m

Current Liabilities

4.2 m4.3 m3.8 m3.1 m3.3 m3.1 m4.4 m2.4 m2.6 m2.2 m2.7 m2.1 m

Total Debt

1.5 m

Additional Paid-in Capital

298.2 m299.6 m308 m312.8 m313.2 m313.3 m313.6 m315.9 m316.2 m316.7 m321.6 m322.9 m

Retained Earnings

(269.1 m)(273.3 m)(281.2 m)(286.1 m)(289.9 m)(295.2 m)(296.5 m)(299.3 m)(303.3 m)(306.8 m)(311.5 m)(313.9 m)

Total Equity

26.8 m23.2 m18.4 m17.5 m16.6 m12.9 m10 m10.2 m9.1 m

Financial Leverage

1.1 x1.1 x1.2 x1.3 x1.3 x1.3 x1.5 x1.6 x1.7 x

Hemispherx BioPharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(16.2 m)(17.5 m)(15.2 m)(7.5 m)

Depreciation and Amortization

671 k665 k941 k1.1 m

Accounts Receivable

Inventories

(1.3 m)

Accounts Payable

(617 k)869 k(196 k)(326 k)

Cash From Operating Activities

(16.8 m)(13.9 m)(16.1 m)(7.4 m)

Cash From Investing Activities

22.3 m2.5 m6.4 m2.9 m

Cash From Financing Activities

(6.8 m)12.8 m9.7 m4.8 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(8.8 m)(13 m)(3.4 m)(8.3 m)(12.1 m)(2.2 m)(3.5 m)(6.3 m)(2.8 m)(2.7 m)(5.1 m)

Depreciation and Amortization

332 k500 k180 k458 k663 k300 k576 k854 k261 k216 k444 k

Accounts Receivable

(41 k)(6 k)(11 k)

Inventories

(480 k)(1 m)(1.3 m)

Accounts Payable

238 k1.2 m236 k189 k97 k182 k178 k(202 k)103 k245 k126 k

Cash From Operating Activities

(6.2 m)(9.9 m)(4.3 m)(9.2 m)(12.7 m)(1 m)(2.3 m)(5.3 m)(3 m)(2.5 m)(5.2 m)

Cash From Investing Activities

(420 k)651 k(192 k)(355 k)2.1 m(60 k)1.6 m2.9 m486 k1 m993 k

Cash From Financing Activities

8.4 m9.7 m5.2 m9.3 m9.7 m1 k162 k4.7 m875 k4.1 m6.4 m

Hemispherx BioPharma Ratios

USDY, 2018

Financial Leverage

1.7 x
Report incorrect company information